IMMB.US Immunotech Laboratories Inc

Healthcare Biotechnology USA Stocks
0.0002 USD
Close of Oct 5, 2026
0.0001 0.0002
Market cap
USD 110.00
P/E
-
P/B
0.01x
ROE
-14.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2009.

Is IMMB.US undervalued?

Graham number

The Graham number of Immunotech Laboratories Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immunotech Laboratories Inc fundamental analysis

No fundamental analysis for Immunotech Laboratories Inc yet.

Immunotech Laboratories Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immunotech Laboratories Inc

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, Cali…

Full company profile